Transcatheter aortic valve replacement in severe aortic stenosis: a review of comparative durability and clinical effectiveness beyond 12 months

Record ID 32014000171
Authors' recomendations: In follow-up longer than 12 months, findings support the use of TAVR as an alternative to conventional surgery in selected high-risk patients with aortic stenosis, with similar clinical outcomes such as mortality and rehospitalization rates, neurologic events, and myocardial infarction. Major vascular complications and neurologic events were more frequent with TAVR. The two methods, TAVR and SAVR, had similar echocardiographic hemodynamic findings. Compared with standard treatment, TAVR was superior with regard to long-term clinical outcomes and improved symptoms. A meta-analysis of larger trials with sensitivity analyses on study design, sample size, baseline characteristics, and surgeon's experience is needed to reconfirm the findings.
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Heart Valve Prosthesis Implantation
  • Aortic Valve
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.